68ga aby-025
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2011 (NCT02095210)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Radiopharmaceutical
ERBB2 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- 68ga aby-025
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06828588 | Early Phase 1 (Phase 1) | Nov 30, 2025 | Vanderbilt University |
| NCT01858116 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Affibody, Biomedical Radiation Sciences, Swedish Cancer Society, Uppsala University |
| NCT02095210 | Phase 1 | Aug 31, 2011 | University of Copenhagen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affibody | For profit | 1 | 0 | 1 | 2013 |
| Biomedical Radiation Sciences | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Swedish Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1